drugset / Trial / NCT03114280
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)
Phase 1/2
Withdrawn
Centre Antoine Lacassagne
GERCOR - Multidisciplinary Oncology Cooperative Group · collabGORTEC · collab
NaSingle-groupOpen-labelTreatment
Summary
Non-randomized phase I/II, open-labeled clinical study, 1-arm, multicenter, of docetaxel (T), cisplatin (P), 5-fluorouracil (F) and pembrolizumab every 21 days for 3 cycles followed by radiotherapy (RT) combined with carboplatin in untreated unresectable locally-advanced Head and Neck Squamous Cell Carcinoma (HNSCC). The TPF and pembrolizumab combination will be called TP²F.
Timeline
- Start
- 2019-03-12
- Primary completion
- 2019-03-12
- Completion
- 2019-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |